Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 8/20 | 1.00 |
| ▸ | MAOA | P21397 | 8/20 | 1.00 |
| ▸ | ACHE | P22303 | 10/20 | 0.83 |
| ▸ | BCHE | P06276 | 2/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | HTR6 | P50406 | 1/20 | 0.83 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rasagiline SCHEMBL2825094 | 1.00 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Azilect SCHEMBL5960892 | 1.00 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL5135147 | 1.00 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL158439 | 1.00 | MAOA (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL27489652 | 0.97 | MAOA (0.95) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2322409 | 0.97 | MAOA (0.95) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2553678 | 0.93 | MAOA (0.88) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL12787613 | 0.91 | MAOB (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2827373 | 0.91 | MAOB (1.00) | MAOAMAOBACHEBCHEADRA2B | |
| Azilect SCHEMBL29605291 | 0.91 | MAOB (1.00) | MAOAMAOBACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595295-B2 | Dosing regimes for treatment of synucleinopathies | PROTHENA BIOSCIENCES LIMITED (IE) | 2026-04-07 | — | — | US | disclosed |
| EP-4716494-A2 | ADAPTIVE DEEP BRAIN STIMULATION FOR SLEEP STAGE TARGETING TO TREAT SLEEP DYSFUNCTION | The Regents of University of California (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250188158-A1 | Treatment of Parkinson's Disease | PROTHENA BIOSCIENCES LTD (IE) | 2025-06-12 | — | — | US | disclosed |
| WO-2025101224-A2 | ADAPTIVE DEEP BRAIN STIMULATION FOR SLEEP STAGE TARGETING TO TREAT SLEEP DYSFUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119499233-A | Application of MAO-B inhibitor in preparation of medicines for treating neurodegenerative diseases | 齐鲁工业大学(山东省科学院) | 2025-02-25 | — | — | CN | disclosed |
| US-20250017885-A1 | TREATMENT OF INCLUSION BODY MYOSITIS WITH PHENYLBUTYRATE AND MONITORING OF TREATMENT | UNIVERSITY OF KANSAS | 2025-01-16 | — | — | US | disclosed |
| US-12084491-B2 | Treatment of Parkinson's disease | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-09-10 | — | — | US | disclosed |
| US-12065702-B2 | Mitochondrial markers of neurodegenerative diseases | FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÉDICA DE BELLVITGE (IDIBELL) S.A. (ES) | 2024-08-20 | — | — | US | disclosed |
| US-20240272180-A1 | SYSTEMS AND METHODS FOR IDENTIFYING AND TREATING NEURODEGENERATIVE DISEASE | CND LIFE SCIENCES, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240180479-A1 | Treatment of Parkinson's Disease | PROTHENA BIOSCIENCES LTD (IE) | 2024-06-06 | — | — | US | disclosed |
| EP-3182987-B1 | HUMANIZED ANTI-TAU ANTIBODIES | C2N DIAGNOSTICS LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116802208-A | Treatment of parkinson's disease | 普罗塞纳生物科学有限公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4211162-A1 | TREATMENT OF PARKINSON'S DISEASE | Prothena Biosciences Limited (IE) | 2023-07-19 | — | — | EP | disclosed |
| CN-116348492-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11554103-B2 | Compositions and methods to reduce pharmaceutical-induced toxicity | NORTHWESTERN UNIVERSITY (US) | 2023-01-17 | — | — | US | disclosed |
| US-20220315651-A1 | Treatment of Parkinson's Disease | HOFFMANN-LA ROCHE INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2022192173-A1 | TREATMENT OF PARKINSON'S DISEASE | PROTHENA BIOSCIENCES LIMITED (IE) | 2022-09-15 | — | — | WO | disclosed |
| CN-106659759-B | Humanized anti-TAU antibodies | C2N诊断有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220098291-A1 | Treatment of Parkinson's Disease | PROTHENA BIOSCIENCES INC | 2022-03-31 | — | — | US | disclosed |
| WO-2022056209-A1 | TREATMENT OF PARKINSON'S DISEASE | PROTHENA BIOSCIENCES LIMITED (IE) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595295-B2 | Dosing regimes for treatment of synucleinopathies | SNCA, MAPT, CHAT | MAOB 1225/4885MAOA 1493/4885ACHE 186/4885 |
| US-11554103-B2 | Compositions and methods to reduce pharmaceutical-induced toxicity | PARK7, SNCA, PRNP | MAOB 54/4885MAOA 79/4885ACHE 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.